Head-to-head evidence
Carisbamate vs Fosphenytoin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Carisbamate
Developed by SK Biopharmaceuticals Co., Ltd.
NCT00425282 · Phase 3 · completed
The study was randomized and double-blind with 566 participants, and its primary endpoint was the clinical measure of change in seizure frequency. However, no results are posted and the registry record does not clearly identify a comparator arm, so the primary endpoint cannot be judged as met or missed.
Next expected readout: February 2027 · NCT05219617 (registry estimate)
Fosphenytoin
Marketed by Pfizer
NCT00908453 · Phase 3 · completed
The study assigned participants to fosphenytoin dose groups without randomization, blinding, or a comparator arm. Its primary safety endpoint cannot be assessed because the registry does not report results, so the evidence remains limited.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Fosphenytoin's landscape